UBX Unity Biotechnology, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
UBX revenue and earnings
- Quarter ended Mar 31, 2025: revenue $0, net income −$7.30M, EPS -0.43
- Quarter ended Dec 31, 2024: revenue n/a, net income −$8.44M, EPS -0.51
- Quarter ended Sep 30, 2024: revenue n/a, net income −$6.48M, EPS -0.38
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.28M, EPS -0.31
Recent UBX insider trades
- Apr 2, 2025: Ghosh Anirvan sold 96,797 shares ($99.7K)
- Apr 2, 2025: Sullivan Lynne Marie sold 21,867 shares ($22.5K)
- Apr 2, 2025: Nguyen Alexander Hieu sold 17,852 shares ($18.4K)
- Mar 27, 2025: Nguyen Alexander Hieu sold 1,954 shares ($2.27K)
5%+ owners
- Alyeska Investment Group, L.P.: 9.2% (Schedule 13G/A, filed May 15, 2025)